远大医药：延缓儿童近视的眼科药物中国IIa期临床首例患者入组

Core Viewpoint - The announcement by Yuan Da Pharmaceutical regarding the completion of the first patient enrollment in the IIa clinical trial for the innovative ophthalmic drug GPN00884 indicates a significant step towards evaluating its efficacy and safety in delaying myopia progression in children [1] Group 1: Clinical Trial Details - The IIa clinical trial is a randomized, double-blind, placebo-controlled study [1] - The trial aims to enroll over 80 participants aged 6 to 12 years with myopia [1] - The primary objective is to evaluate the effectiveness of GPN00884 eye drops in delaying the progression of myopia in children and to assess its safety profile [1]